Back to Search
Start Over
Infliximab for refractory ulcerative proctitis
- Source :
- Alimentary Pharmacology & Therapeutics. 31:1178-1185
- Publication Year :
- 2010
- Publisher :
- Wiley, 2010.
-
Abstract
- Aliment Pharmacol Ther 31, 1178–1185 Summary Background Efficacy of infliximab in treating ulcerative proctitis remains unknown. Aim To evaluate the clinical, biological and endoscopic efficacy of infliximab therapy in refractory proctitis. Methods The charts of 420 patients treated with infliximab for ulcerative colitis were reviewed. Thirteen patients were treated with infliximab for refractory ulcerative proctitis in six referral centres between 2005 and 2009. Results Following infliximab therapy induction, 9/13 patients (69%) had a complete response (defined as absence of diarrhoea and blood), 2/13 (15%) had a partial response and 2/13 (15%) were primary nonresponders. The median follow-up was 17 months (range, 3–48). Among the 11 patients with clinical response after infliximab induction therapy, 9 (82%) patients maintained response at last follow-up. Disappearance of rectal disorders was observed in all nine patients who maintained clinical response at last follow-up. Following infliximab induction therapy, the mean CRP level fell from 12.8 mg/L to 4.7 mg/L. Endoscopic evaluation was performed before and after infliximab in seven patients, showing an improvement in mucosal lesions in four patients, persistent mild endoscopic activity in two patients and no improvement in one patient. One patient underwent proctocolectomy. Conclusion Infliximab therapy seems to be effective in inducing and maintaining a clinical response in refractory ulcerative proctitis.
- Subjects :
- musculoskeletal diseases
medicine.medical_specialty
medicine.medical_treatment
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Refractory
Internal medicine
Induction therapy
medicine
Pharmacology (medical)
Colitis
Proctitis
Hepatology
business.industry
Proctocolectomy
medicine.disease
Ulcerative colitis
Infliximab
3. Good health
Surgery
Ulcerative proctitis
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
business
medicine.drug
Subjects
Details
- ISSN :
- 13652036 and 02692813
- Volume :
- 31
- Database :
- OpenAIRE
- Journal :
- Alimentary Pharmacology & Therapeutics
- Accession number :
- edsair.doi...........c3121fbb655b43b3b4b6030234872df9